Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial.

ABSTRACT:

SUBMITTER: Goodman SG 

PROVIDER: S-EPMC10547267 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature